ClinicalTrials.gg
CompletedNCT06823388Updated Dec 18, 2025

Assessment of Acupuncture on Eye Fatigue

An interventional study of acupuncture and pseudo-acupuncture in Acupuncture, Eye Fatigue and Accomodation, sponsored by Chung Shan Medical University. Completed at 1 site in Taiwan. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-18.

Sponsored by Chung Shan Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is designed to assess the effiacy of acupuncutre on eye fatigue. The indicator of eye fatigue is eye accommodation ability. Patients will be randomly assigned to the experimental group and the control group. The experimental group will receive acupuncture treatment, while the control group will receive sham acupuncture stimulation. The eye accommodation ability of both groups will be easured before and after the intervention, and the differences in eye accommodation ability before and after treatment will be analyzed.

Read the detailed description

A dual-arm, parallel, randomized single-blind, sham-controlled trial will be conducted. The aim of the study is to assess the effiacy of acupuncutre on eye fatigue. Patients will be recruited from outpatient clinics. Subjects will be assessed at a Traditional Chinese Medicine (TCM) outpatient clinic and then have their accommodation function tested in an optometry room . This will determine if they meet the inclusion criteria.

Those who meet the inclusion criteria will be randomly assigned to the experimental group or the control group. The experimental group will receive treatment at seven acupuncture points: Fengfu (GV16), bilateral Fengchi (GB20), Yumen (TH2), and Hegu (LI4), using Jiasun 42G 1-inch acupuncture needles. The needles will be inserted perpendicularly to achieve the "De Qi" sensation, with a depth of 0.5 inches, and retained for 25 minutes before removal. The control group will undergo sham acupuncture at the same points using specially designed acupuncture needles from the manufacturer, which give the sensation of needling but retract into the handle without penetrating the skin, thus providing no real stimulation. Both groups will be treated by TCM physician .

After needle removal, visual acuity will be tested again to compare the differences in values between the pre- and post-test measurements of both groups.

02

Conditions studied

  • Acupuncture
  • Eye Fatigue
  • Accomodation

Browse trials for

Keywords

  • eye fatigue
  • acupuncture
03

In context

Asthenopia

67 studies on the registry are indexed under Asthenopia; 10 are open to participants now.

This study's enrollment of 30 is below the median of 56 across 56 interventional studies indexed under Asthenopia.

Browse Asthenopia studies →

Lead sponsor

Chung Shan Medical University is the lead sponsor of 125 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjective experience of eye fatigue after using electronic devices at least twice a week.
  • Age ≥ 18 years.
  • Agreement to sign the form for this study.

Exclusion criteria

Exclusion Criteria:

  • Accommodation assessment: Interocular accommodation difference greater than 3 diopters (D).
  • History of metabolic diseases with accompanying retinal conditions (e.g., diabetic retinopathy, hypertensive/hyperlipidemic patients with macular edema, retinal hemorrhage, glaucoma, etc.).
  • Current treatment for ocular inflammation or infection (e.g., conjunctivitis, orbital cellulitis).
  • Underwent eye surgery within the last 3 months (including LASIK surgery).
  • Received acupuncture treatment for eye-related symptoms in the past month.
  • Diagnosed with severe ophthalmic conditions (e.g., optic atrophy) and deemed unsuitable for the trial by an ophthalmologist.
  • Diagnosed with anemia, hypotension, or chronic fatigue in the past three months, making them unsuitable for acupuncture due to a tendency to faint.
  • Pregnant women.
  • Major diseases such as renal insufficiency, cerebrovascular disease, or cancer, deemed unsuitable for clinical research participation by the principal investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    acupuncture group

    Device: acupuncture

  • Placebo comparator
    pseudo-acupuncture group

    Device: pseudo-acupuncture

Interventions

  • Deviceacupuncture

    acupuncture

  • Devicepseudo-acupuncture

    The pseudo-acupuncture device can simulate the sensation of acupuncture stimulation.

06

What researchers measure

Primary outcomes

  1. eye accommodation ability

    Value of eye accommodation ability difference before and after the intervention, measured by an autorefractor

    Time frame: From enrollment to the end of treatment in 30 minutes

07

Study locations

1 site
  • Chung Shan Medical University Hospital
    Taichung, 400, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — eye accomodation ability

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Dec 2024, 4 months.

Of 31 non-industry interventional studies with no phase under Asthenopia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's 4 months is above that.

Counting every sponsor, half of 38 studies reached it within 3 months; a quarter within 2 and three quarters within 9.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Feb 12, 2025
StartActual
Aug 1, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
May 30, 2025
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06823388
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Aug 1, 2024
Primary completion
Dec 30, 2024
Completion
May 30, 2025
Last update
Dec 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion